The FDA announced on Wednesday (5/27) new guidances via a Q&A format for how COVID-19 is impacting formal meetings, effective immediately. The guidance outlines that all meetings with the FDA will be held remotely, either through teleconference or video conference. The FDA also outlined that it will be continuing its generic drug program application assessment activities, however as the “…FDA identifies more potential generic drug shortages, we may need to shift resources to address urgent public health needs.” 

Read more here

More on: